PUBLICATIONS:

Peer Reviewed

♦ Co-authored by trainees

§ Co-authored by Post-Doc

^ Co-authored by Grad Students

# Co-authored by Medical Students

1. Vose JM, Fu K, Wang L, Mansoor A, Stewart D, Cheng H, Smith L, Yuan J, Wureishi HN, Link BK, Cessna MH, Barr PM, Kahl BS, Mckinney MS, Khan N, Advani RH, Martin P, Goy AH, Phillips TJ, Mehta A, Kamdar M, Crump M, Pro B, Flowers CR, Jacobson CA, Smith SA, Stephens DM, Vachanova V, Jin Z, Wu S, Hernandez-Ilizaliturri F, Torka P, Anampa-Guzman A, Kashef F, Li X, Sharma S, Greiner TC, Armitage JO, Lunning M, Weisenburger DD, Bociek RG, Iqbal J, Yu G, and Bi C on behalf of the North American Mantle Cell Lymphoma Consortium.    Integrative analysis of clinicopatholigical features define novel prognostic models for mangle cell lymphoma in the immunochemotherapy era:  A report from The North American Mantle Cell Lymphoma Consortium.  J Hematol & Oncol.  In Press.  2023.

Role:    Conception and design; conduction of experiments, provision of patient samples; collection and assembly of data; data analysis and interpretation; manuscript writing; final approval of manuscript.

2. Zelenetz AD, Gordon LI, Abramson JS, Advani RH, Andreadis B, Barlette NL, Budde LE, Caimi PF, Chang FE, Christian B, DeVos S,  Dholaria B, Fayad LE, Habermann TM, Hamid MS, Hernandez-Ilizaliturri F, Hu B, Kaminski MS, Karimi Y, Kelsey CR, King R, Krivacic S, LaCasce AS, Lim M, Messmer M, Narkhede M, Rabinovitch R, Ramikrishnan P, Reid E, Roberts KB, Saeed H, Smith SD, Svoboda J, Swinnen LJ, Tuscano J, Vose JM, Dwyer MA, Sundar H.  NCCN Guidelines Insights: B-cell lymphoma, Version 6.2023.  J Natl Compr Canc Netw  21(11):1118-1131, 2023.  PMID: 37935098

Role:    Conception and design; conduction of experiments, provision of patient samples; collection and assembly of data; data analysis and interpretation; manuscript writing; final approval of manuscript.

3. Gerson JN, Handorf E, Villa D, Gerrie AS, Chapani P, Li S, Medeiros LJ, Wang ML, Cohen J, Churnetski MC, Hill BT, Sawalha Y, Hernandez-Ilizaliturri FJ, Kothari SK, Vose JM, Bast MA< Fenske TS, Narayana Rao Gari S, Maddocks KJ, Bond DA, Bachanova V, Kolla B, Chavez JC, Shah BD, Lansigan F, Burns TF, Donovan A, Wagner-Johnston ND, Massmer MR, Mehta A, Anderson J, Reddy N, Kovach A, Landsburg DJ, Glenn MJ, Inwards DJ, Ristow K, Karmali R, Kaplan J, Caimi PF, Rajguru SA, Evens AM, Klein AK, Umyarova E, Pulluri B, Amengaul JE, Lue JK, Diefenbach C, Fisher RI, Barta SK. Outcomes of patients with blastoid and pleomorphic variant mantle cell lymphoma. Blood Adv 2023:bloodadvances.2023010757. [eput ahead of print: doi: 10.1182/bloodadvances2023010757]  PMID: 37874912

Role: Conception and design; provision of patient samples; collection and assembly of data; data analysis and interpretation; manuscript writing; final approval of manuscript.

4. Gulati S, Husu CY, Shah S, Shah PK, Zon R, Alsamari S, Awosika J, El-Bakouny Z, Bashir B, Beeghly A, Berg S, de-la-Rosa-Martinez D, Doroshow DB, Egan PC, Fein J, Flora DB,Friese CR, Fromowitz A, Griffiths EA, Swang C, Jani C, Joshi M, Khan H, Klein EJ, Heater NK, Koshkin VS, Kown DH, Labaki C, Latif T, McKay RR, Nagaraj G, Nakasome ES, Nonato T, Polimera HV, Puc M, Razavi P, Ruiz-Garcia E. Saliby RM, Shastri A, Singh SPK, Tagalasis V, Vilar-Compte D, Weissmann LB, Wilkins CR, Wise-Draper TM, Wotman MT, Yoon JJ, Mishra S, Grivas P, Shyr Y, Warnder JL, Connors JM, Shah DP, Rosovsky RP, COVID-19 and Cancer Consortium.  Systemic anticancer therapy and thromboembolic outcomes in hospitalized patients with cancer and COVID-19.  JAMA Oncol 9(10):61390-1400, 2023.  PMID: 37589970

Role:    Conception and design; conduction of experiments, provision of patient samples; collection and assembly of data; data analysis and interpretation; manuscript writing; final approval of manuscript.

5. Wang ML, Jurczak W, Zinzani PL, Eyre TA, Cheah CY, Ujjani CS, Koh Y, Izutsu K, Gerson JN, Flinn I, Tessoulin B, Alencar AJ, Ma S, Lewis D, Lech-Maranda E, Rhodes J, Patel K, Maddocks K, Lamanna N, Wang Y, Tam CS, Munir T, Hagai H, Hernandez-Ilizaliturri F, Kumar A, Fenske TS, Seymour FJ, Zelentetz AD, Nair B, Tsai DE, Balbas M, Walgren RA, Abada P, Wang C, Zhao J, Mato AR, Shah NN. Pirtobrutinib in covalent bruton tyrosine kinase inhibitor pretreated mantle cell lymphoma.  J Clin Oncol 41(24):3988-3997, 2023.  PMID: 37192437

Role:    Conception and design; conduction of experiments, provision of patient samples; collection and assembly of data; data analysis and interpretation; manuscript writing; final approval of manuscript.

6. Lin LH, Ghasemi M, Burke SM, Mavis CK, Nichols JR, Torka P, Mager DE, Hernandez-Ilizaliturri FJ, Goey AK.   Population pharmacokinetics and pharmacodynamics of carfilzomib in combination with rituximab, ifosfamide, carboplatin, and Etoposide in adult patients with relapsed/refractory diffuse large B-cell lymphoma.  [Epub ahead of print doi.org/10.1007/s11523-023-00992-4]  Targeted Oncol 18(5):685-695, 2023.  PMID: 37632592

Role:    Conception and design; conduction of experiments, provision of patient samples; collection and assembly of data; data analysis and interpretation; manuscript writing; final approval of manuscript.

7. Mato  AR, Woyach JA, Brown JR, Ghia P, Patel K, Eyre TA, Munir T, Lech-Maranda E, Lamanna N, Tam CS, Shah NN, Cooms CC, Ujjani CS, Fakhri B, Cheah CY, Patel MR, ALencar AJ, Cohen JB, Gerson JN, Flinn IW, Ma S, Jagadeesh D, Rhodes JM, Hernandez-Ilizaliturri F, Zinzani PL, Seymour FJ, Balbas M, Nair B, Abada P, Wang C, Ruppert AS, Wang D, Tsai DE, Wierda WG, Jurczak W.  Pirtobrutinib after a covalent BTK inhibitor in chronic lymphocytic leukemia.  N Engl J Med 389(1):33-44, 2023.  PMID: 37407001

Role:   Data collection and assembly; provision of study material; manuscript writing; final approval of manuscript; conception and design; conduction of experiments, provision of patient samples; data analysis and interpretation.

8. § # Torka P, Russell T, Mavis C, Gu J, Ghione P, Barth M, Hernandez-Ilizaliturri FJ.  AMG176, an MCL-1 inhibitor, is active in pre-clinical models of aggressive B-cell lymphomas.  Leuk Lymphoma 64(6):1175-1185, 2023.  PMID: 37074033

Role:   Conception and design; conduction of experiments, provision of patient samples; collection and assembly of data; data analysis and interpretation; manuscript writing; final approval of manuscript.

9. Wang X, Chen C, Vuong D, Rodriguez S, Lam V, Roleder C, Wang J, Kambhampati S, Berger A, Pennock N, Torka P, Hernandez-Ilizaliturri F, Siddiqi T, Wang L, Xia Z, Danilov A.  Pharmacologic targeting of Nedd8-activating enzyme reinvigorates T cell responses in lymphoid neoplasia.  Leukemia 37(6):1324-1335, 2023.  PMID: 37031300

Role:   Conception and design; conduction of experiments, provision of patient samples; collection and assembly of data; data analysis and interpretation; manuscript writing; final approval of manuscript.

10. Przespolewski ER, Baron J, Kashef F, Fu K, Jani Sait SN, Hernandez-Ilizaliturri F, Thompson J.  Concomitant venetoclax and imatinib for comanaging chronic lymphocytic leukemia and chronic myeloid leukemia:  A case report. J Natl Compr Canc Netw 1(2):102-107, 2023.  PMID: 36791756

Role:   Data collection and assembly; provision of study material; manuscript writing; final approval of manuscript; conception and design; conduction of experiments, provision of patient samples; data analysis and interpretation.

11. Torka P, Kambhampati S, Chen L, Wang X, Chen C, Vuong D, Qin H, Muir A, Orand K, Borja I, Smith D, Herrera A, Sprugeon S, Park B, Lewis L, Hernandez-Ilizaliturri F, Xia Z, Danilov A.  Peveonedistat, a Nedd8-activating enzyme inhibitor, in combination with ibrutinib in patients with relapsed/refractory B-cell non-Hodgkin lymphoma.  Blood Cancer Journal.  13(1):9, 2023.  PMID: 36631449

Role:   Conception and design; conduction of experiments, provision of patient samples; collection and assembly of data; data analysis and interpretation; manuscript writing; final approval of manuscript.

12. Abramson JS, Solomon SR, Arnason J, Johnston PB, Glass B, Bachanova V, Ibrahimi S, Mielke S, Mutasers P, Hernandez-Ilizaliturri F, Izutsu K, Morschhauser F, Lunning M, Crotta A, Montheard S, Previtali A, Ogasawara K, Kamdar M for the TRANSFORM investigators.  Lisocabtagene Maraleucel as second-line treatment for Large B-cell lymphoma.  Primary analysis of phase 3 TRANSFORM study.  [epub ahead of print] doi.org/10.1182/blood.2022018730.  Blood 141(14):1675-1684, 2023.  PMID: 36542826

Role:    Data collection and assembly; provision of study material; manuscript writing; final approval of manuscript; conception and design; conduction of experiments, provision of patient samples; data analysis and interpretation.

13. Torka P, Groman A, Wong JT, Nichols J, Kader A, Mavis C, Anampa-Guzman A, Sait SNJ, Block A, Przespolewski E, Mohr A, Lund I, McWhite KM, Kostrewa J, DeMarco J, Johnson M, Darrall A, Thomas R, Sundaram S, Ghione P, Hutson A, Hernandez-Ilizaliturri FJ.  Carfilzomib combined with rituximab, ifosfamide, carboplantin, and etoposide for relapsed or refractory DLBCL.  [epub ahead of print] doi: 10.1182/bloodadvances.2022008543. Blood Adv 7(7):1146-1155, 2022.   PMID: 36375132

Role:    Data collection and assembly; provision of study material; manuscript writing; final approval of manuscript; conception and design; conduction of experiments, provision of patient samples; data analysis and interpretation.

14. Bakouny Z, Labaki C, Grover P, Awosika J, Gulati S, Hsu CY, Alimohamed SI, Bashir B, Berg S, Bilen MA, Bowles D, Castellano C, Desai A, Elkrief A, Eton OE, Fecher LA, Flora D, Galsky MD, Gatti-Mays ME, Gesenhues A, Glover MJ, Gopalakrishnan D, Gupta S, Halfdanarson TR, Hayes-Lattin B, Hendawi M, Hsu E, Hwang C, Jandarov R, Jani C, Johnson DB, Joshi M, Khan H, Khan SA, Knox N, Koshkin VS, Kulkarni AA, Kwon DH, Matar S, McKay RR, Mishra S, Moria FA, Nizam A, Nock NL, Nonato TK, Panasci J, Pomerantz L, Portuguese AJ, Provenzano D, Puc M, Rao YJ, Rhodes TD, Riely GJ, Ripp JJ, Rivera AV, Ruiz-Garcia E, Schmidt AL, Schoenfeld AJ, Schwartz GK, Shah SA, Shaya J, Subbiah S, Tachiki LM, Tucker MD, Valdez-Reyes M, Weissmann LB, Wotman MT, Wulff-Burchfield EM, Xie Z, Yang YJ, Thompson MA, Shah DP, Warner JL, Shyr Y, Choueiri TK, Wise-Draper TM; COVID-19 and Cancer Consortium. Interplay of immunosuppression and immunotherapy among patients with cancer and COVID-19.  [epub ahead of print] doi: 10.1001/jamaoncol.2022.5357. JAMA Oncol9(1):128-134, 2022.   PMID: 3636731

Role:    Conception and design; conduction of experiments, provision of patient samples; collection and assembly of data; data analysis and interpretation; manuscript writing; final approval of manuscript.

15. Lama R, Xu C, Galster SL, Querol-Garcia J, Portwood S, Mavis CK, Ruiz FM, Martin D, Wu J, Giorgi MC, Bargonetti G, Wang ES, Hernandez-Ilizaliturri FJ, Koudelka GB, Chemler SR, Munoz IG, Wang X.  Small molecule MMRi62 targets MDM4 for degradation and induces leukemic cell apoptosis regardless of p53 status.  Front Oncol 12:933466, 2022 eCollection.  PMID: 3592795

Role:    Conception and design; conduction of experiments, provision of patient samples; collection and assembly of data; data analysis and interpretation; manuscript writing; final approval of manuscript

16. Kamdar M, Solomon SR, Arnason J, Johnston PB, Glass B, Bachanova V, Ibrahimi S, Mielke S, Mutsaers P, Hernandez-Ilizaliturri F, Izutsu K, Morschhauser F, Lunning M, Maloney DG, Crotta A, Montheard S, Previtali A, Stepan L, Ogasawara K, Mack T, Abramson JS, for the TRANSFORM Investigators.  Lisocabtagene Maraleucel versus standard of care with salvage chemotherapy followed by autologous stem cell transplantation as second-line treatment in patients with relapsed or refractory large B-cell lymphoma (TRANSFORM): results from an interim analysis of an open-label, randomized, phase 3 trial.  Lancet 399:2294-2308, 2022.  PMID: 35717989

Role:    Data collection and assembly; provision of study material; manuscript writing; final approval of manuscript; conception and design; conduction of experiments, provision of patient samples; data analysis and interpretation.

17. Wierda WG, Brown J, Abramson JS, Awan F, Bilgrami SF, Bociek G, Brander D, Chanan-Khan AA, Coutre SE, Davis RS, Eradat H, Fletcher CD, Gaballa S, Ghobadi A, Hamid MS, Hernandez-Ilizaliturri F, Hill B, Kaesberg P, Kamdar M, Kaplan LD, Khan N, Kipps TJ, Ma S, Mato A, Mosse C, Schuster S, Siddiqi T, Stephens DM, Ujjani C, Wagner-Johnston N, Woyach JA, Ye JC, Dwyer MA, Sundar H. NCCN Guidelines Insights: Chronic lymphocytic leukemia/small lymphocytic lymphoma.  Version 3.2022.  J Natl Compr Cancer Netw 20(6):622-634, 2022.  PMID: 35714675

Role:    Data analysis and interpretation; manuscript revision; final approval of manuscript

18. ♦Zablonski K, Wong J, Hernandez-Ilizaliturri FJ.  Oncology Case Challenge: A retired man with left upper quadrant pain, leukocytosis.  Medscape, Case Challenge.  5/4/2022.

Role:    Data collection and assembly; provision of study material; manuscript writing; final approval of manuscript; conception and design; conduction of experiments, provision of patient samples; data analysis and interpretation.

19. Torka P, Akhtar OS, Reddy N, Baysal B, Kader A, Groman A, Nichols J, Mavis C, Tario J, Block AMW, Sait SJ, Ghione P, Sundaram S, Przespolewski E, Mohr A, Lund I, Kostrewa J, McWhite K, Demarco J, Johnson M, Darrall An, Thomas R, Wallace P, Neppalli V, Hutson A, Hernandez-Ilizaliturri FJ.  Ofatumumab plus HyperCVAD/HD-MA induction leads to high rates of minimal residual disease (MRD) negativity in patients with newly diagnosed mantle cell lymphoma, Results of a phase 2 study.  [epub ahead of Print]  doi:10.1002/cncr.34106.  Cancer 128(8):1595-1604, 2022. PMID: 35157306

Role:    Conception and design; conduction of experiments, provision of patient samples; collection and assembly of data; data analysis and interpretation; manuscript writing; final approval of manuscript

20. ♦Akhtar OS, Groman A, Singh A, Ghione P, Lund I, Hernandez-Ilizaliturri FJ, Torka P.  Frequency and timing of other primary cancers in patients with chronic lymphocytic leukemia (CLL): a 17-year longitudinal study.  [epub ahead of print] 2/13/22  DOI: 10.1080/10428194.2021.2012662.  Leuk Lymphoma 63(5):1127-1136, 2022. PMID: 35152821

Role:    Conception and design; conduction of experiments, provision of patient samples; collection and assembly of data; data analysis and interpretation; manuscript writing; final approval of manuscript

21. Gregory GP, Kumar S, Wang D, Mahadevan D, Walker P, Wagner-Johnson N, Escobar C, Bennerji R, Bhutani D, Chang J, Hernandez-Ilizaliturri F, Klein A, Pagel JM, Rybka W, Yee AJ, Mohrbacher A, Huang M, Farooqu7i M, Marinello P, Quach H.  Pembrolizumab plus dinaciclib in patients with hematological malignancies: the phase 1b KEYNOTE-155 study.  [epub ahead of print] DOI: 10.1182/bloodadvances.2021005872.  Blood Advances 6(4):1232-1242, 2022.  PMID: 34972202

Role: Data collection and assembly; provision of study material; manuscript writing; final approval of manuscript; conception and design; conduction of experiments, provision of patient samples; data analysis and interpretation.

22. Zelenetz AD, Gordon LI, Chang JE, Christian B, Abramson JS, Advani RH, Bartlett NL, Budde LE, Caimi PF, De Vos S, Dholaria B, Fakhri B, Fayad LE, Glenn MJ, Habermann TM, Hernandez-Ilizaliturri F, Hsi E, Hu B, Kaminski MS, Kelsey CR, Khan N, Krivacic S, LaCasce AS, Lim M, Narkhede M, Rabinovitch R, Ramakrishnan P, Reid E, Roberts KB, Saeed H, Smith SD, Svoboda J, Swinnen LJ, Tuscano J, Vose JM, Dwyer MA, Sundar H. NCCN Guidelines Insights: B-cell lymphomas, Version 5.2021.  J Natl Compr Canc Netw 19(11):1218-1230, 2021.  PMID: 34781267.

Role:    Data analysis and interpretation; manuscript revision; final approval of manuscript

23. Ghione P, Gu J, Attwood K, Torka P, Sundaram S, Mavis C, Johnson M, Thomas R, McWhite K, Darrall A, DeMarco J, Kostrewa J, Mohr A, Rivas L, Neiders M, Suresh L, Griffiths E, Ramsperger V, Shen L, Hernandez-Ilizaliturri F, Goel S.  Impaired humoral responses to COVID-19 vaccination in patients with lymphoma receiving B-cell directed therapies. Doi: 10.1182/blood.2021012443 [epub ahead of print].  Blood 138(9):811-814, 2021. PMID: 34189565

Role: Data collection and assembly; provision of study material; manuscript writing; final approval of manuscript; conception and design; conduction of experiments, provision of patient samples; data analysis and interpretation.

24. Farrugia MK, Morrison C, Hernandez-Ilizaliturri F, Aljabab S.  A dose-response relationship for cutaneous lesions of Langerhans cell histiocytosis.  Doi: 10.1155/2021/6680635  Case Rep Oncol Med. eCollection 2021.

Role: Data collection and assembly; provision of study material; manuscript writing; final approval of manuscript; conception and design; conduction of experiments, provision of patient samples; data analysis and interpretation.

25. Sundaram S, Jizzini M, Lamonica D, Attwood K, Gravina M, Hernandez-Ilizaliturri FJ, Torka P.  Utility of bone marrow aspirate and biopsy in staging of patients with T-cell lymphoma in the PET-Era – Tissue remains the issue.  Leukemia & Lymphoma 61(13): 3226-3233, 2020.  PMID: 32749169

Role: Data analysis and interpretation; manuscript revision; final approval of manuscript.

26. Liu Y, Gu JJ, Yang L, Tsai PC, Guo Y, Xue K, Xia Z, Liu X, Lv F, Cao J, Hong X, Mavis C, Hernandez-Ilizaliturri FJ, Zhang Q.  The adhesion molecule ICAM-1 in diffuse large B-cell lymphoma post-rituximab era: Relationship with prognostic importance and rituximab resistance.  Doi: 10.18632/aging.202180. [epub ahead of print]. Clinical Cancer Research 13(1):181-193, 2020.  PMID: 33288735

Role: Conception and design; provision of patient samples; collection and assembly of data; data analysis and interpretation; manuscript writing; final approval of manuscript.

27. Singh AR, Gu JJ, Zhang Q, Torka P, Sundaram S, Mavis C, Hernandez-Ilizaliturri FJ.  Metformin sensitizes therapeutic agents and improves outcome in pre-clinical and clinical diffuse large B-cell lymphoma.  [EPub ahead of print: doi.org/10.1186/s40170-020-00213-w] Cancer & Metabolism 8:10, 2020. PMID: 32647571

Role: Conception and design; conduction of experiments, provision of patient samples; collection and assembly of data; data analysis and interpretation; manuscript writing; final approval of manuscript.

28. Kaplan LD, Maurer MJ, Stock W, Bartlett NL, Fulton N, Pettinger A, Byrd JC, Blum KA, LaCasce AS, His ED, Liu YT, Scott DW, Hurd D, Ruppert AS, Hernandez-Ilizaliturri F, Leonard JP, Cheson BD.  Bortezomib consolidation or maintenance following immunochemotherapy and autologous stem cell transplantation for mantel cell lymphoma: CALGB/Alliance 50403,  Mar 13; doi:10.1002/ajh.25783. [Epub ahead of print]. Am J of Hem.  95(6):583-593, 2020.  PMID: 32170769

Role:  Data collection and assembly; provision of study material; manuscript writing; manuscript revision; final approval of manuscript.

29. Torka P, Mavis C, Kothari S, Belliotti S, Gu J, Sundaram S, Barth M, Hernandez-Ilizaliturri FJ.  Pevonedistat, a NEDD8-activating enzyme inhibitor, induces apoptosis and augments efficacy of chemotherapy and small molecule inhibitors in pre-clinical models of diffuse large B-cell lymphoma.  Doi.org/10.1002/jha2.2 [Epub ahead of print]. eJHaem 1(1):122-132, 2020.  PMID: 33073261

Role: Conception and design; conduction of experiments, provision of patient samples; collection and assembly of data; data analysis and interpretation; manuscript writing; final approval of manuscript.

30. Hoppe RT, Advani RH, Ai WZ, Ambinder RF, Armand P, Bello CM, Benitez CM, Bierman PJ, Boughan KM, Dabaja B, Gordon LI, Hernandez-Ilizaliturri FJ, Herrera AF, Hochberg EP, H7uang J, Johnston PB, Kaminski MS, Kenkre VP, Khan N, Lynch RC, Maddocks K, McConathy J, McKinney M, Metzger M, Morgan D, Mulroney C, Raminovitch R, Rosenspire KC, Seropian S, Tao R, Winter JN, Yahalom J, Burns JL, Ogba N.  Hodgkin Lymphoma, version 2.2020, NCCN Clinical Practice Guidelines in Oncology.  J Natl Compr Canc Netw  18(6):755-781, 2020.  PMID: 3250297

Role: Data analysis and interpretation; manuscript revision; final approval of manuscript

31. Peringeth G, Torka P, Wong J, Hernandez-Ilizaliturri FJ.  Successful treatment of paraneoplastic cholestasis in relapsed/refractory Hodgkin’s lymphoma with bridging therapy and checkpoint blockade.  Mar 13; doi 10.1016/j.clml.2020.01.013 [Epub ahead of print].  Clin Lymphoma, Myeloma Leuk 20(6):e316-e319, 2020.  PMID: 32179034

Role: Data analysis and interpretation; manuscript revision; final approval of manuscript.

32. Torka P, Kothari SK, Sundaram S, Li S, Medeiros LJ, Ayers EC, Landsburg DJ, Bond DA, Maddocks KJ, Giri An Hess B, Pham LQ, Advani R, Liu Y, Barta SK, Vose JM, Churmetski MC, Cohen JB, Burkart M, Karmali R, Zurko J, Mehta A, Olszewski AJ, Lee S, Hill BT, Burns TF, Lansigan F, Rabinovich E, Peace D, Groman A, Attwood K, Hernandez-Ilizaliturri FJ.  Outcomes of patients with limited-stage aggressive large B-cell lymphoma with high-risk cytogenetics.  Blood Advances 4(2):253-262, 2020. PMID: 31945157

Role: Data collection and assembly; provision of study material; manuscript writing; manuscript revision; final approval of manuscript.

33. Herr MM, Torka P, Zhang Y, Wallace PK, Tario JD Jr, Repasky EA, Chen GL, Ho CM, Balderman SR. Ross M, Paiva B, Hernandez-Ilizaliturri FJ, McCarthy PL, Hahn T.  Immune profiling in diffuse large B-cell lymphoma and mantle cell lymphoma patients treated with autologous hematopoietic cell transplant.  Bone Marrow Transplant 55(1):272, 2020. PMID: 31471573

Role: Data analysis and interpretation; manuscript revision; final approval of manuscript

34. Torka P, Barth M, Ferdman R, Hernandez-Ilizaliturri FJ.  Mechanisms of resistance to monoclonal antibodies (mAbs) in lymphoid malignancies.  Curr Hematol Malig Rep 14(5):426-438, 2019.  PMID: 31559580

Role: Data analysis and interpretation; manuscript revision; final approval of manuscript

35. Zelenetz AD, Gordon LI, Abramson JS, Advani RH, Bartlett NL , Caimi PF, Change JE, Chavez JC, Christian B, Fayad LE, Glenn MJ, Habermann TM, Lee Harris N, Hernandez-Ilizaliturri F, Kaminski MS, Kelsey CR, Khan N, Drivacic S, LaCasce AS, Mehta A, Nademanee A, Rabinovitch R, Reddy N, Reid E, Roberts KB, Smith SD, Snyder ED, Swinnen LJ, Vose JM, Dwyer MA, Sundar H.  NCCN Guidelines Insights: B-Cell lymphomas, Version 3.2019.  J Natl Compr Canc Netw 17(6):650-661, 2019.  PMID: 31500358

Role: Data analysis and interpretation; manuscript revision; final approval of manuscript

36. Gerson JN, Handorf E, Villa D, Gerrie AS, Chapani P, Li S, Medeiros LJ, Wang MI, Cohen JB, Calzada O, Churnetski MC, Hill BT, Sawalha Y, Hernandez-Ilizaliturri FJ, Kothari S♦, Vose JM, Bast MA, Fenske TS, Narayana Rao Gari S, Maddocks KJ, Bond D, Bachanova V, Kolla B, Chavez J, Shah B, Lansigan F, Burns TF, Donovan AM, Wagner-Johnston N, Messmer M, Mehta A, Anderson JK, Reddy N, Kovach AE, Landsburg DJ, Glenn M, Inwards DJ, Karmali R, Kaplan JB, Caimi PF, Rajguru S, Evens A, Klein A, Umyarova E, Pulluri B, Amengual JE, Lue JK, Diefenbach C, Fisher RI, Barta SK. J. Survival outcomes of younger patients with mantle cell lymphoma treated in the Rituximab era.   Clin Oncol 37(6): 471-480; 2019. PMID: 30615550.

Role:  Data collection and assembly; provision of study material; manuscript writing; manuscript revision; final approval of manuscript.

37. Akhtar OS♦, Attwood K, Lund I, Hare R, Hernandez-Ilizaliturri FJ, Torka P. Dose reductions in ibrutinib therapy are not associated with inferior outcomes in patients with chronic lymphocytic leukemia (CLL). Leuk Lymphoma. Jan 2:1-6. doi: 10.1080/10428194.2018.1554862. [Epub ahead of print]. 2019 PMID: 30601100.

Role:  Conception and design; provision of patient samples; collection and assembly of data; data analysis and interpretation; manuscript writing; final approval of manuscript.

38. Runckel K^, Barth MJ, Mavis C, Gu JJ, Hernandez-Ilizaliturri FJ. The SMAC mimetic LCL-161 displays antitumor activity in preclinical models of rituximab-resistant B-cell lymphoma. Blood Adv. 2:3516-3525; 2018. PMID: 30530779.

Role:  Conception and design; conduction of experiments, provision of patient samples; collection and assembly of data; data analysis and interpretation; manuscript writing; final approval of manuscript.

39. Badar T, Hamadani M, Bachanova V, Maddocks KJ, Umyarova E, Chavez JC, Epperla N, Chhabra S, Xavier AC, Karmali R, Salhab M, Reddy N, Glenn MJ, Hernandez-Ilizaliturri FJ, Flowers CR, Evens AM, Zhou Z, Lansigan F, Barta SK, Cohen JB, Fenske TS, Costa LJ. Efficacy of salvage chemotherapy in diffuse large B cell lymphoma with primary treatment failure according to putative cell of origin. Leuk Lymphoma. 2:1-7; 2018. PMID: 30277110.

Role:  Data collection and assembly; provision of study material; manuscript writing; manuscript revision; final approval of manuscript.

40. Etter JL, Cannioto R, Soh KT, Alquassim E, Almohanna H, Dunbar Z, Joseph JM, Balderman S, Hernandez-Ilizaliturri FJ, Moysich KB.  Lifetime physical inactivity is associated with increased risk for Hodgkin and non-Hodgkin lymphoma: A case-control study.  Leuk Res 69:7-11, 2018.  PMID: 29609041

Role: Data analysis and interpretation; manuscript revision; final approval of manuscript.

41. Bhatti M, Ippolito T, Mavis C, Gu J§, Gairo MS, Lim MS, Hernandez-Ilizaliturri F, Barth MJ.  Pre-clinical activity of targeting the PI3K/Akt/mTOR pathway in Burkitt Lymphoma.  Ontotarget 9(31):21820-21830, 2018.  PMID: 29774105

Role: Data analysis and interpretation; manuscript revision; final approval of manuscript.

42. Rohl R, Bax D, Schierer S, Bogner PN, Hernnadez-Ilizaliturri F, Paragh G.  A Case for histologic verification of the diagnosis of atypical psoriasis before systemic therapy.  JAAD Case Rep 4(5):465-467, 2018.

Role: Data analysis and interpretation; manuscript revision; final approval of manuscript.

43. Hoppe RT, Advani RH, Ai WZ, Ambinder RF, Aoun P, Armand P, Bello CM, Benitz CM, Bierman PJ, Chen R, Dabaja B, Dean R, Forero A, Gordon LI, Hernandez-Ilizaliturri FJ, Hochberg EP, Huang J, Johnson PB, Kaminski MS, Kenkre VP, Khan N, Maddocks K, Maloney DG, Metzger M, Moore JO Morgan D, Moskowitz CH, Mulroney C, Rabinovitch R, Seropian S, Tao R, Winter JN, Yahalom J, Burns JL, Ogba N.  NCCN Guidelines insights: Hodgkin lymphoma. Version 1.2018 J Natl Compr Canc Netw 16(3):245-254, 2018.  PMID: 29523663

Role:  Data analysis and interpretation; manuscript revision; final approval of manuscript.

44. Vachhani P♦, Neppalli VT, Cancino CJ, Bogner P, Roche CL, Paragh G, Grassi MA, Hernandez-Ilizaliturri FJ.  Radiograhical imaging and bone marrow biopsy in staging of cutaneous B-cell lymphoma.  Br J Haematol 2018.  doi: 10.1111/bjh.15154. [Epub ahead of print] 184:634-696, 2019.  PMID: 29468663

Role:  Data analysis and interpretation; manuscript revision; final approval of manuscript.

45. Gu JJ§, Singh A♦, Xue K♦, Mavis C, Barth M, Yanamadala V, Lenz P, Grau M, Lenz G, Czuczman MS, Hernandez-Ilizaliturri FJ. Up-regulation of hexokinase II contributes to rituximab-chemotherapy resistance and is a clinically relevant target for therapeutic development. Oncotarget. 9: 4020-33, 2018.  PMID: 29423101

Role:  Conception and design; conduction of experiments, provision of patient samples; collection and assembly of data; data analysis and interpretation; manuscript writing; final approval of manuscript.

46. Torka P, Patel P, Tan W, Wilding G, Bhat SA, Czuczman MS, Lee KP, Deeb G, Neppalli V, Mavis C, Wallace P, Hernandez-Ilizaliturri FJ.  A Phase II trial of rituximab combined with pegfilgrastim in patients with indolent B-cell non-Hodgkin lymphoma.  Clin Lymphoma Myeloma Leuk.  18(1):e51-e60, 2018.  PMID: 29233743

Role:  Data analysis and interpretation; manuscript revision; final approval of manuscript.

47. Pilchowska M, Pittaluga S, Ferry JA, Chang H, Kanakry JA, Sehn LH, Feldman T, Abramson JS, Kritharis A, Hernandez-Ilizaliturri FJ, Lossos IS, Press OW, Fenske TS, Friedberg JW, Vose JM, Blum KA, Jagadeesh D, Woda B, Gupta GK, Gascoyne RD, Jaffe ES, Evens AM.  Clinicopathologic consensus study of gray zone lymphoma with features intermediate between DLBCL and classical HL.  Blood AV 1(26):2600-2609, 2017.  PMID: 29296913

Role:  Data analysis and interpretation; manuscript revision; final approval of manuscript.

48. Yang Y, Qui J, Snyder-Keller A, Wu Y, Sun S, Sui H, Dean AB, Kramer L, Hernandez-Ilizaliturri FJ.  Fatal cache valley virus meningoencephalitis associated with rituximab maintenance therapy.  [Epub ahead of print] Am J Hematol 93(4):590-594, 2018. PMID: 29282755

Role:  Data analysis and interpretation; manuscript revision; final approval of manuscript.

49. Winter AM, Landsburg DJ, Mato AR, Isaac K, Hernandez-Ilizaliturri FJ, Reddy N, Smith S, Shadman M, Smith MR, Caimi P, Jagadesh D, Hill BT.  A multi-international outcomes analysis of patients with relapsed or refractory DLBCL treated with ibrutinib.  [Epub ahead of print] doi:10.1182/blood-20217-05-786988.  Blood 130:1676-1679, 2017.  PMID: 28794071

Role:  Data analysis and interpretation; manuscript revision; final approval of manuscript.

50. Epperla N, Maddocks KJ, Salhab M, Chavez JC, Reddy N, Karmali R, Umyarova E, Bachanova V, Costa C, Glenn M, Calzada O, Xavier AC, Zhou Z, Hossain NM, Hernandez-Ilizaliturri FJ, Al-Mansour Z, Barta SK, Chhabra S, Lansigan F, Mehta A, Jaglal MV, Evans A, Flowers CR, Cohen JB, Fenske TS, Hamadani M, Costa LJ.  C-MYC+ Relapsed and Refractory Diffuse Large B-Cell Lymphoma: Impact of Additional “Hits” and Outcomes with Subsequent Therapy.  Doi: 10.1002/cncr.30895 [Epub ahead of print]  Cancer  123:4411-4418, 2017  PMID: 28749548

Role:  Data analysis and interpretation; manuscript revision; final approval of manuscript.

51. Hoppe RT, Advani RH, Ai WZ, Ambiner RF, Aoun P, Bello CM, Benitez CM, Bernat K, Bierman PJ, Blum KA, Chen R, Dabaja B, Forero A, Gordon LI, Hernandez-Ilizaliturri FJ, Hochberg EP, Huang J, Johnston PB, Kaminski MS, Kenkre VP, Khan N, Maloney DG, Mauch PM, Metzger M, Moore JO, Morgan D, Moskowitz CH, Mulroney C, Poppe M, Rabinovitch R, Seroplan S, Smith M, Winter JN, Yahalom J, Burn J, Ogba N, Sundar H.  Hodgkin Lymphoma Version 1.2017.  NCCN clinical practice guidelines in oncology.  J Natl Compr Cancer Netw  15(5):608-638, 2017.  PMID: 28476741

Role:  Data analysis and interpretation; manuscript revision; final approval of manuscript.

52. Kothari S♦, Hernandez-Ilizaliturri FJ, Torka P.  Striking a happy medium.  J Clin Oncol.  Doi: 10.1200/JCO.2017.73.9839 [EPub ahead of print]  PMID: 28682685

Role:  Data analysis and interpretation; manuscript revision; final approval of manuscript.

53. Evren S, Khoury T, Neppalli V, Cappuccino H, Hernandez-Ilizaliturri FJ, Kumar P.  Breast implant-associated anaplastic large cell lymphoma (ALCL): A case report.  Am J Case Rep 18:605-610, 2017.  PMID: 28559535.

Role:  Data analysis and interpretation; manuscript revision; final approval of manuscript.

54. Landsburg DJ, Falkiewicz MK, Maly J, Blum KA, Howlett C, Feldman T, Mato AR, Hill BT, Li S, Medeiros LJ, Torka P, Hernandez-Ilizaliturri FJ, Reddy NM, Singavi A, Fenske TS, Chavez JC, Kaplan JB, Behdad A, Petrich AM, Bast MA, Vose JM, Olszewski AJ, Costa C, Lansigan F, Gerson JN, Barta SK, Calzada O, Cohen JB, Lue JK, Amengual JE, Rivera X, Persky DO, Peace DJ, Nathan S, Cassaday RD.  Outcomes of patients with double-hit lymphoma who achieve first complete remission.  J Clin Oncol 2017 May 5:JCO22017722157 doi: 10.1200/JCO.2017.72.2157.  [Epub ahead of print].  35(20):2260-2267, 2017.  PMID: 28475457

Role:  Data analysis and interpretation; manuscript revision; final approval of manuscript.

55. Wierda WG, Zelenetz AD, Gordon LI, Abramson JS, Advani RH, Andreadis CB, Bartlett N, Byrd JC, Caimi P, Fayad LE, Fisher RI, Glenn MJ, Habermann TM, Harris NL, Hernandez-Ilizaliturri FJ, Hoppe RT, Horwitz SM, Kaminski MS, Kelsey CR, Kim YH, Krivacic S, LaCasce AS, Martin MG, Nademanee A, Porcu P, Press O, Rabinovitch R, Reddy N, Reid E, Roberts K, Saad AA, Snyder ED,Sokol L, Swinnen LJ, Vose JM, Yahalom J, Dwyer MA, Sundar H.  NCCN Guidelines Insights: Chronic Lymphocytic Leukemia/Small Lymphocytic Leukemia, Version 1.2017.  J Natl Compr Cancer Netw 5(3):293-311, 2017.  PMID: 28275031

Role:  Data analysis and interpretation; manuscript revision; final approval of manuscript.

56. Czuczman MS, Trneny M, Davies A, Rule S, Linton KM, Wagner-Johnson N, Gascoyne RD, Slack GW, Brousset P, Eberhard DA, Hernandez-Ilizaliturri F, Salles G, Witzig TE, Zinzani PL, Wright GW, Staudt LM, Yang Y, Williams PM, Luh C-J, Russo J, Thakurta A, Hagner P, Fustier P, Song D, Lewis ID.  A phase 2/3 multicenter, randomized, open-label study to compare the efficacy and safety of lenalidomide versus investigator’s choice in patients with relapsed or refractory diffuse large B-cell lymphoma.  Clin Cancer Res doi:10.1158/1078-0432.CCR-16-2818. [Epub ahead of print] 2017.  23(15):4127-4137, 2017. PMID: 28381416

Role:  Data analysis and interpretation; manuscript revision; final approval of manuscript.

57. Jewell RC, Kipps TJ, Durig J, Griskevicius L, Stilgenbauer S, Smolej L, Mayer J, Hess G, Hernandez-Ilizaliturri FJ, Padmanabhan-Iyer S, Fang L, Goldstein N, Gorczyca M, Gupta I, Lisby S, Wierda WG for the Hx-CD20-407 Study Investigators.   Associations of ofatumumab exposure and treatment outcomes in patients with CLL receiving chemoimmunotherapy.  Leuk Lymphoma 58(2):348-356, 2017.  PMID: 27389174

Role:  Data analysis and interpretation; manuscript revision; final approval of manuscript.

58. Gu JJ§, Kaufman GP♦, Mavis C, Czuczman MS, Hernandez-Ilizaliturri FJ.  Mitotic catastrophe and cell cycle arrest are alternative cell deasth pathways executed by bortezomib in rituximab resistant B-cell lymphoma cells.  Oncotarget, 2016 Dec 31. Doi: 10.18632/oncotarget. 14405 [Epub ahead of print].  8(8):12741-12753, 2017.  PMID: 28055975

Role:  Data analysis and interpretation; manuscript revision; final approval of manuscript.

59. Costa LJ, Maddocks K, Epperla N, Reddy NM, Karmali R, Umyarova E, Bachanova V, Costa C, Glenn M, Chavez J, Calzada O, Lansigan F, Nasheed H, Barta S, Zhou Z, Jaglal M, Chhabra S, Hernandez-Ilizaliturri F, Xavier AC, Mehta A, Peker D, Forero-Torres A, Al-Mansour Z, Evens AM, Cohen JB, Flowers CR, Fenske TS, Hamadani M.  Diffuse large B-cell lymphoma with primary treatment failure: Ultra-high risk features and benchmarking for experimental therapies.  Am J Hematol 92(2):161-170, 2017.  PMID: 27880984

Role:  Data analysis and interpretation; manuscript revision; final approval of manuscript.

60. Landsburg DJ, Falkiewicz MK, Petrich Am, Chu BA, Behdad A, Li S, Mediros LJ, Cassaday RD, Reddy NM, Bast MA, Vose JM, Kruczek KR, Smith SE, Patel P, Hernandez-Ilizaliturri F, Karmali R, Rajguru S, Yang DT, Maly JJ, Blum KA, Zhao W, Vanslambrouck C, Nabhan C.  Sole rearrangement but no amplification of MYC is associated with a poor prognosis in patient with diffuse large B-cell lymphoma and B-cell lymphoma unclassifiable.  Britis J of Haematol 175(4):631-640, 2016.  PMID: 27469075

Role:  Data analysis and interpretation; manuscript revision; final approval of manuscript.

61. Horwitz SM, Zelenetz AD, Gordon LI, Wierda WG, Abramson JS, Advani RH, Andreadis CB, Bartlett N, Byrd JC, Fayad LE, Fisher RI, Glenn MJ, Habermann TM, Lee Harris N, Hernandez-Ilizaliturri F, Hoppe RT, Kaminski MS, Kelsey CR, Kim YH, Krivacic S, LaCasce AS, Lunning M, Nademanee A, Press O, Rabinovitch R, Reddy N, Reid E, Roberts K, Saad AA, Sokol L, Swinnen LJ, Vose JM, Yahalom J, Zafar N, Dwyer M, Sundar H, Porcu P.  J NCCN 14(9):1067-1079, 2016.  PMID: 27587620

Role:  Data analysis and interpretation; manuscript revision; final approval of manuscript.

62. Batlevi CL, Kasamon Y, Bociek RG, Lee P, Gore L, Copeland A, Sorensen R, Ordentlich P, Cruickshank S, Kunkel L, Buglio D, Hernandez-Ilizaliturri F, Younes A.  ENGAGE-501: Phase 2 study of etinostate (SNDX-275) in relapsed and refractory Hodgkin lymphoma.  Haematologica 101(8):968-975, 2016.  E-pub 2016x.  PMID: 27151994

Role:  Data analysis and interpretation; manuscript revision; final approval of manuscript.

63. Xue K♦, Gu JJ§, Zhang Q, Liu X, Wang J, Li XQ, Luo J, Hernandez-Ilizaliturri FJ, Fernandez SF, Czuczman MS, Cao J, Hong X, Guo Y.  Cardiotoxicity as indicated by LVEF and troponin T sensitivity following two anthracycline-based regimens in lymphoma: Results from a randomized prospective clinical trial.  Oncotarget 7(22):32519-32531, 2016 doi: 10.18632/oncotarget.8685 [epub ahead of print].  PMID: 27081036

Role:  Data analysis and interpretation; manuscript revision; final approval of manuscript.

64. Smonskey M, Lasorsa E, Rosario S, Kirk JS, Hernandez-Ilizaliturri FJ, Ellis L.  EZH2 inhibition re-sensitizes multidrug resistant B-cell lymphomas to etoposide mediated apoptosis.  Oncoscience 3(1):21-30, 2016 eCollection.  PMID: 26973857

Role:  Data analysis and interpretation; manuscript revision; final approval of manuscript.

65. Zelenetz AD, Gordon LI, Wierda WG, Abramson JS, Advani RH, Andreadis CB, Bartlett N, Byrd JC, Fayad LE, Fisher RI, Glenn MJ, Habermann TM, Lee Harris N, Hernandez-Ilizaliturri F, Hoppe RT, Horowitz SM, Kaminski MS, Kelsey CR, Kim YH, Krivacic S, LaCasce AS, Lunning M, Nademanee A, Porcu P, Press O, Rabinovitch R, Reddy N, Reid E, Roberts K, Saad AA, Sokol L, Swinnen LJ, Vose JM, Yahalom J, Zafar N, Dwyer M, Sundar H.  Diffuse large B-cell lymphoma version 1.2016.  J Natl Compr Canc Netw 14(2):196-231, 2016.  PMID: 26850490

Role:  Data analysis and interpretation; manuscript revision; final approval of manuscript.

66. Lasorsa E, Smonskey M, Kirk J, Dalimov Z, Rosario S, Hernandez-Ilizaliturri F, Ellis L,.  Mitochondrial protection impairs BET bromodomain inhibitors mediated cell death and rovides rationale for combination therapeutic strategies.   Cell Death and Disease (2015) 6, e2014; doi:10.1038/cddis.2015.352

Role:  Data analysis and interpretation; manuscript revision; final approval of manuscript.

67. Czuczman N#, Barth MJ, Gu J§, Neppalli V, Mavis C, Frys S#, Klener P, Vockova P, Czuczman MS, and Hernandez-Ilizaliturri FJ. Pevonedistat, a NEDD8 Activating Enzyme Inhibitor, is active in Mantle Cell Lymphoma and Enhances Rituximab Activity in vivo. Blood 2015.  Dec 16. pii: blood-2015-04-640920. [Epub ahead of print]  PMID: 26675347

Role:  Conception and design; conduction of experiments, provision of patients samples; collection and assembly of data; data analysis and interpretation; manuscript writing; final approval of manuscript.

68. Xue K♦, Gu JJ§, Zhang Q, Mavis C, Hernandez-Ilizaliturri FJ, Czuczman MS, Guo Y.  Vorinostat, a histone deacetylase (HDAC) inhibitor, promotes cell cycle arrest and re-sensitizes rituximab- and chemo-resistant lymphoma cells to chemotherapy agents.  J Cancer Res Clin Oncol. 142(2):379-387, 2016.  Epub ahead of print 8/28/15.  PMID: 26314218.

Role:  Data analysis and interpretation; manuscript revision; final approval of manuscript.

69. Evens AM, Kanakry JA, Sehn LH, Kritharis A, Feldman T, Kroll A, Gascoyne RD, Abramson JS, Petrich AM, Hernandez-Ilizaliturri FJ, Al-Mansour Z, Adeimy C, Hemminger J, Bartlett NL, Mato A, Caimi PF, Advani RH, Klein AK, Nabhan C, Smith SM, Fabergas JC, Lossos IS, Press OW, Fenske TS, Friedberg JW, Vose JM, Blum KA.  Gray zone lymphoma with features intermediate between classical Hodgkin lymphoma and diffuse large B-cell lymphoma: Characteristics, outcomes, and prognostication among a large multicenter cohort.  Am J Hematol. 90(9):778-783, 2015.  Epub ahead of print 6/4/15.  PMID: 26044261

Role:  Conception and design; provision of study materials or patients; collection and assembly of data; data analysis and interpretation; manuscript writing; final approval of manuscript.

70. Hoppe RT, Advani RH, Ai WZ, Ambinder RF, Aoun P, Bello CM, Benitez CM, Bierman PJ, Blum KA, Chen R, Dabaja B, Forero A, Gordon LI, Hernandez-Ilizaliturri FJ, Hochberg EP, Huang J, Johnston PB, Khan N, Maloney DG, Mauch PM, Metzger M, Moore JO, Morgan D, Moskowitz CH, Mulroney C, Poppe M, Rabinovitch R, Seropian S, Tsien C, Winter JN, Yahalom J, Burns JL, Sundar H.  Hodgkin lymphoma, version 2.2015.  J Natl Compr Canc Netw.  13(5):554-586, 2015.  PMID: 25964641

Role:  Data analysis and interpretation; manuscript revision; final approval of manuscript.

71. Barth M, Mavis C, Czuczman MS, and Hernandez-Ilizaliturri FJ. Ofatumumab exhibits enhanced in vitro and in vivo activity compared to rituximab in pre-clinical models of mantle cell lymphoma. Clinical Cancer Research 21(19):4391-7497, 2015. Epub ahead of print 5/11/15.  PMID: 25964296

Role:  Conception and design; conduction of experiments, provision of patients samples; collection and assembly of data; data analysis and interpretation; manuscript writing; final approval of manuscript.

72. Witzig TE, Nowakowski GS, Habermann TM, Goy A, Hernandez-Ilizaliturri FJ, Chiappella A, Bitolo U, Fowler N. Czuczman MS.  A comprehensive review of lenalidomide therapy for B-cell non-Hodgkin lymphoma.  Annals of Oncology. 26(8):1667-77, 2015.   Epub 2015/02/26. PMID: 25712458

Role:  Data analysis and interpretation; manuscript writing; final approval of manuscript.

73. Frys S#, Simons Z♦, Hu Q, Bath MJ, Gu JJ§, Mavis C, Skitzki J, Song L, Czuczman MS, Hernandez-Ilizaliturri FJ.  Etinostat, a novel histone deacetylase inhibitor is active in B-cell lymphoma and enhances the anti-tumor activity of rituximab and chemotherapy agents.  British Journal of Haematology.  169:506-5019, 2015.  Epub 2015/02/26 PMID: 25712263

Role:  Conception and design; conduction of experiments, provision of patients samples; collection and assembly of data; data analysis and interpretation; manuscript writing; final approval of manuscript.

74. Castillo JJ, Chavez JC♦, Hernandez-Ilizaliturri FJ, Montes-Moreno S. CD20-negative diffuse large B-cell lymphomas: Biology and emerging therapeutic options.  Expert Review in Hematology. 8(3):343-354, 2015.  PMID: 25641215

Role:  Conception and design; collection and assembly of data; data analysis and interpretation; manuscript writing; final approval of manuscript.

75. Thudium KE♦, Wollenberg L, Mavis C, Gu J§, Fetterly GJ, Czuczman MS, Hernandez-Ilizaliturri FJ.  Novel pharmacodynamic approach to assess Obatoclax (GX15-070) and Bortezomib (BTZ) synergism in Non-Hodgkin’s Lymphoma.  Clinical Cancer Drugs.  In Press.

Role:  Conception and design; conduction of experiments, provision of patients samples; collection and assembly of data; data analysis and interpretation; manuscript writing; final approval of manuscript.

76. Klanova M, Lorkova L, Vit O, Maswabi B, Molinsky J, Pospisilova J, Mavis C, Lateckova L, Kulvait V, Vejmelkova D, Jaksa R, Hernandez F, Trneny M, Vokurka M, Petrak J, Klener P.  Downregulation of deoxycytidine kinase in cytarabine-resistant mantle cell lymphoma cells confers cross-resistance to nucleoside analogs gemcitabine, fludarabine and cladribine, but not to other classes of anti-lymphoma agents.  Molecular Cancer.  13:159-173, 2014. Epub 2014/06/29.  PMID: 24972933

            Role:  Provision of samples; collection and assembly of data; data analysis and interpretation; manuscript writing; final approval of manuscript.

77. Klanova M, Soukup T, Jaksa R, Molinsky J, Lateckova L, Maswabi B, Prukova D, Brezinova J, Vockova P, Hernandez-Ilizialiturri F, Kulvait V, Zivny J, Vokurka M, Necas E, Trneny M, Klener P.  Mouse models of mantle cell lymphoma: complex changes in gene expression and phenotype of engrafted MCL cells: implications for preclinical research.  Laboratory Investigation.    94(7):806-817, 2014. Epub 2014/05/28.  PMID: 24862967

Role:  Conception and design; conduction of experiments, provision of patients samples; collection and assembly of data; data analysis and interpretation; manuscript writing; final approval of manuscript.

78. Goy A, Hernandez-Ilizaliturri FJ, Kahl B, Ford P, Protomastro E, Berger M. A phase I/II study of the pan Bcl-2 inhibitor obatoclax mesylate plus bortezomib for relapsed or refractory mantle cell lymphoma. Leukemia and Lymphoma. Epub 2014/05/06. DOI: 10.3109/10428194.2014.907891.  55(12):2761-2768, 2014.  PMID: 24679008

Role:  Provision of study materials or patients; collection and assembly of data; data analysis and interpretation; manuscript writing; final approval of manuscript.

79. Kun L, Hernandez-Ilizaliturri FJ, Reddy NM. Novel therapeutic strategies for cutaneous T-cell lymphoma in advanced stages. Semin Hematol. 51:35-41, 2014.  PMID: 24468314

Role:  Collection and assembly of data; data analysis and interpretation; manuscript writing; final approval of manuscript

80. Petrich AM, Gandhi M, Jovanovic B, Castillo JJ, Rajguru S, Yang DT, Shah KA, Whyman JD, Lansigan F, Hernandez-Ilizaliturri FJ, Lee LX, Barta SK, Melinamani S, Karmali R, Adeimy C, Smith S, Dalal N, Nabhan C, Peace D, Vose J, Evens AM, Shah N, Fenske TS, Zelenetz AD, Landsburg DJ, Howlett C, Mato A, Jaglal M, Chavez JC, Tsai JP, Reddy N, Li S, Handler C, Flowers CR, Cohen JB, Blum KA, Song K, Sun H, Press O, Cassaday R, Jaso J, Medeiros LJ, Sohani AR, Abramson JS.  Impact of induction regimen and stem cell transplantation on outcomes in double-hit lymphoma: a multicenter retrospective analysis.  Blood 124(15):2354-2361, 2014.  PMID: 25161267

Role:  Conception and design; provision of patients samples; collection and assembly of data; data analysis and interpretation; manuscript writing; final approval of manuscript

81. Gandhi S♦, Kallab AM, Hernandez-Ilizaliturri FJ. Diffuse large cell lymphoma. Medscape Reference. Updated 1/6/14. Available at: http://emedicine.medscape.com/article/202969-overview. 

Role:  Conception and design; collection and assembly of data; data analysis and interpretation; manuscript writing; final approval of manuscript

82. Straus DJ, Duvic M, Horwitz SM, Hymes K, Goy A, Hernandez-Illizaliturri FJ, Feldman T, Wegner B, Myskowski PL.  Final Results of Phase II trial of doxorubicin HC1 liposome injections followed by Bexarotene in Advanced Cutaneous T-Cell Lymphoma.  Annals of Oncology.  25:206-210, 2014.  PMID: 24285015

Role:  Conception and design; provision of study materials or patients; collection and assembly of data; data analysis and interpretation; manuscript writing; final approval of manuscript.

83. Evens AM, Advani R, Press OW, Lossos IS, Vose JM, Hernandez-Ilizaliturri FJ, Robinson BK, Otis S, Dagan LN, Abdallah R, Kroll-Desrosiers A, Yarber JL, Sandoval J, Foyil K, Parker LM, Gordon LI, Blum KA, Flowers CR, Leonard JP, Habermann TM, Bartlett NL.  Lymphoma occurring during pregnancy: Antenatal therapy, complications, and maternal survival in a multicenter analysis.  J Clin Oncol. 31(32):4132-4139, 2013. PMID: 24043736

Role:  Conception and design; provision of study materials or patients; collection and assembly of data; data analysis and interpretation; manuscript writing; final approval of manuscript.

84. Gu JJ§, Hernandez-Ilizaliturri FJ, Mavis C, Czuczman NM#, Deeb G, Gibbs J, Skitzki JJ, Patil R♦, Czuczman MS.  MLN2238, a proteasome inhibitor, induces caspase-dependent cell death, cell-cycle arrest, and potentiates the cytotoxic activity of chemotherapy agents in rituximab-chemotherapy sensitive or resistant B-cell lymphoma pre-clinical models.  Anti-Cancer Drugs.  24(10):1030-1038, 2013. PMID: 23995855

Role:  Conception and design; provision of patients samples; collection and assembly of data; data analysis and interpretation; manuscript writing; final approval of manuscript

85. Gu JJ§, Hernandez-Ilizaliturri FJ, Kaufman GP♦, Czuczman NM#, Mavis C, Skitzki JJ, Czuczman MS. The novel proteasome inhibitor carfilzomib induces cell cycle arrest, apoptosis and potentiates the anti-tumour activity of chemotherapy in rituximab-resistant lymphoma. British journal of haematology. 162(5):657-69, 2013. PMID: 23826755

Role:  Conception and design; provision of patients samples; collection and assembly of data; data analysis and interpretation; manuscript writing; final approval of manuscript

86. Wenzel SS, Grau M, Mavis C, Hailfinger S, Wolf A, Madle H, Deeb G, Dorken B, Thome M, Lenz P, Dirnhofer S, Hernandez-Ilizaliturri FJ, Tzankov A, Lenz G. MCL1 is deregulated in subgroups of diffuse large B-cell lymphoma. Leukemia. 27(6):1381-90, 2013. PMID: 23257783

Role:  Conception and design; provision of patients samples; collection and assembly of data; data analysis and interpretation; manuscript writing; final approval of manuscript

87. Hernandez-Ilizaliturri FJ.  The evolving role of Brentuximab vedotin in the management of CD30-positive lymphoma.  Intl J of Targeted Therapies in Cancer.  November, 2012:44-48.

Role:  Conception and design; collection and assembly of data; data analysis and interpretation; manuscript writing; final approval of manuscript.

88. Hernandez-Ilizaliturri FJ.  Evolving therapeutic strategies in patients with relapsed/refractory Hodgkin lymphoma.  American Society of Clinical Oncology Educational Book.  2011 339-345

Role:  Conception and design; collection and assembly of data; data analysis and interpretation; manuscript writing; final approval of manuscript.

89. Czuczman MS, Chanan-Khan AA, Skipper M, Mohr A, Bernstein ZP, Brady WE, Hernandez-Ilizaliturri FJ.  Phase I/II study of rituximab in combination with liposomal doxorubicin (Doxil) in patients with relapsed/refractory B-cell lymphoma:  Clinical efficacy without cardiac toxicity.  Leukemia & Lymphoma. In Press.

Role:  Provision of study materials or patients; collection and assembly of data; data analysis and interpretation; manuscript writing; final approval of manuscript.

90. Darwar R♦ and Hernandez-Ilizaliturri FJ.  The emerging role of lenalidomide in the management of mantle cell lymphoma (MCL).  Best Practice & Research Clinical Haematology 25(2):185-190, 2012. PMID: 22687454

Role:  Conception and design; collection and assembly of data; data analysis and interpretation; manuscript writing; final approval of manuscript.

91. Hoppe RT, Advani RH, Ai WZ, Ambinder RF, Aoun P, Bello CM, Bierman PJ, Blum KA, Chen R, Dabaja B, Duron Y, Forero A, Gordon LI, Hernandez-Ilizaliturri FJ, Hochberg EP, Maloney DG, Mansur D, Mauch PM, Metzger M, Moore JO, Morgan D, Moskowitz CH, Poppe M, Pro B, Winter JN, Yahalom J, Sundar H.  Hodgkin lymphoma, version 2.2012 featured updates to the NCCN Guidelines.  J Natl Compr Cancer Netw 10:589-597, 2012. PMID: 22570290

Role:  Conception and design; collection and assembly of data; data analysis and interpretation; manuscript writing; final approval of manuscript.

92. Barth MJ, Hernandez-Ilizaliturri FJ, Mavis C, Tsai PC^, Gibbs JF, Deeb G, Czuczman MS. Ofatumumab demonstrates activity against rituximab-sensitive and -resistant cell lines, lymphoma xenografts and primary tumour cells from patients with B-cell lymphoma. Br J Haematol 2012; 156:490-498. PMID: 22150234

Role:  Conception and design; provision of patients samples; collection and assembly of data; data analysis and interpretation; manuscript writing; final approval of manuscript

93. Tsai P-C^, Hernandez-Ilizaliturri FJ, Bangia N, Olejniczak SH^, Czuczman MS.  Regulation of CD20 in rituximab-resistant cell lines (RRCL) and B-cell non-Hodgkin lymphoma (B-NHL).  Clinical Cancer Research.  18:1039-1050, 2012. PMID: 22228637

Role:  Conception and design; conduction of experiments, provision of patients samples; collection and assembly of data; data analysis and interpretation; manuscript writing; final approval of manuscript

94. Anderson KC, Alsina M, Bensinger W, Biermann JS, Cohen AD, Devine S, Djulbegovic B, Faber EA Jr, Gasparetto C, Hernandez-Ilizaliturri F, Huff CA, Kassim A, Krishnan AY, Medeiros BC, Meredith R, Raje N, Schriber J, Singhal S, Somlo G, Stockerl-Goldstein K, Treon SP, Tricot G, Weber DM, Yahalom J, Yunus F, Kumar R, Shead DA; NCCN (National Comprehensive Cancer Network). Waldenström's macroglobulinemia/lymphoplasmacytic lymphoma, version 2.2013. J Natl Compr Canc Netw. 2012 Oct 1;10(10):1211-9.  PMID: 23054875

Role:  Conception and design; collection and assembly of data; data analysis and interpretation; manuscript writing; final approval of manuscript.

95. Vaidyanathan G♦, Ngamphaiboon N♦, Hernandez-Ilizaliturri FJ.  Clinical spectrum and prognosis of follicular lymphoma with blastoid transformation:  Case series and a review of the literature.  Annals of Hematology. 90: 955-962, 2011. PMID: 21286717

Role:  Conception and design; collection and assembly of data; data analysis and interpretation; manuscript writing; final approval of manuscript.

96. Hoppe RT, Advani RH, Ai WZ, Ambinder RF, Bello CM, Bierman PJ, Blum KA, Dabaja B, Duron Y, Forero A, Gordon LI, Hernandez-Ilizaliturri FJ, Hochberg EP, Maloney DG, Mansur D, Mauch PM, Metzger M, Moore JO, Morgan D, Moskowitz CH, Poppe M, Pro B, Weiss L, Winter JN, Yahalom J; NCCN Hodgkin Lymphoma. Hodgkin’s Lymphoma. J Natl Compr Canc Netw. 2011;9:1020-58. PMID: 21917626

Role:  Conception and design; provision of study materials or patients; collection and assembly of data; data analysis and interpretation; manuscript writing; final approval of manuscript.

97. Brem E#, Thudium K♦, Khubchandani S♦, Tsai P^, Olejniczak SH^, Bhat S♦, Riaz W♦, Gu J§, Iqbal A♦, Campagna R, Knight J, Mavis C, Hosking P, Deeb G, Gibbs JF, Fetterly G, Czuczman MS, and Hernandez-Ilizaliturri FJ. Distinct cellular and therapeutic effects of obatoclax in rituximab-sensitive and -resistant lymphomas. British Journal of Hematology. 153(5):599-611, 2011. PMID: 21492126

Role:  Conception and design; conduction of experiments, provision of patients samples; collection and assembly of data; data analysis and interpretation; manuscript writing; final approval of manuscript

98. Hernandez-Ilizaliturri FJ, Deeb G, Zinzani PL, Pileri SA, Malik F♦, Macon WR, Witzig TE, Goy A, and Czuczman MS. Higher response to lenalidomide in relapsed/refractory diffuse large B-cell lymphoma in nongerminal center B-cell-like than in germinal center B-cell-like phenotype.  Cancer. Article first published online: 14 APR 2011   DOI: 10.1002/cncr.26135. 117: 5058-5066, 2011.  PMID: 21495023

Role:  Conception and design, provision of patients samples; collection and assembly of data; data analysis and interpretation; manuscript writing; final approval of manuscript

99. Wierda WG, Kipps TJ, Dürig J, Griskevicius L, Stilgenbauer S, Mayer J, Smolej L, Hess G, Griniute R, Hernandez-Ilizaliturri FJ, Padmanabhan S, Gorczyca M, Chang CN, Chan G, Gupta I, Nielsen TG, Russell CA; 407 Study Investigators. Chemoimmunotherapy with O-FC in previously untreated patients with chronic lymphocytic leukemia. Blood 2011; 117:6450-8. PMID: 21498674.

Role:  Provision of study materials or patients; collection and assembly of data; data analysis and interpretation; manuscript writing; final approval of manuscript.

100. Sher T, Ailawadhi S♦, Miller KC, Manfredi D, Wood M, Tan W, Wilding G, Czuczman MS, Hernandez-Ilizaliturri FJ, Hong F, Sood R, Soniwala S, Lawrence W, Jamshed S, Masood A, Iancu D, Lee K, Chanan-Khan A. A steroid-independent regimen of bortezomib, liposomal doxorubicin and thalidomide demonstrate high response rates in newly diagnosed multiple myeloma patients. Br J Haematol. 2011 Jul;154(1):104-10. PMID: 21554260

Role:  Provision of study materials or patients; collection and assembly of data; data analysis and interpretation; manuscript writing; final approval of manuscript.

101. Chanan-Khan A, Lawrence D, Padmanabhan S, Miller A, Hernandez-Ilizaliturri F, Czuczman MS, Wallace PK, Zeldis JB, Lee K.  Tumor Flare Reaction Associated With Lenalidomide Treatment in Patients With Chronic Lymphocytic Leukemia Predicts Clinical Response.  Cancer 117:2127-2135, 2011.  PMID: 21523725

Role:  Manuscript writing; final approval of manuscript.

102. Reist E, Elefante A, Hernandez-Ilizaliturri F. Emerging agents and regimens in the management of follicular lymphomas.  The Oncology Nurse. 4(3):16-17, 2011.

Role:  Conception and design; provision of study materials or patients; collection and assembly of data; data analysis and interpretation; manuscript writing; final approval of manuscript.

103. Castillo, J.J., Beltran, B.E., Bibas, M., Bower, M., Collins, J.A., Cwynarski, K., Diez-Martin, J.L., Hernandez-Ilizaliturri, F., Horwitz, S.M., Montoto, S., Pantanowitz, L., Ribera, J.M. & Vose, J.M. Prognostic factors in patients with HIV-associated peripheral T-cell lymphoma: a multicenter study. Am J Hematol, 86, 256-261, 2011. PMID: 21328430

Role:  Conception and design; collection and assembly of data; data analysis and interpretation; manuscript writing; final approval of manuscript.

104. Hernandez-Ilizaliturri F and Batoo S♦.  The emerging role of lenalidomide in the management of lymphoid malignancies.  Therapeutic Advances in Hematology. 2(1):45-53,2011. PMID: 23556075

Role:  Conception and design; collection and assembly of data; data analysis and interpretation; manuscript writing; final approval of manuscript.

105. Vaidyanathan G♦, Ngamphaiboon N♦, Hernandez-Ilizaliturri FJ. Clinical spectrum and prognosis of follicular lymphoma with blastoid transformation: case series and a review of the literature. Ann Hematol. 2011 Aug;90(8):955-62. PMID: 21286717

Role:  Conception and design; provision of study materials or patients; collection and assembly of data; data analysis and interpretation; manuscript writing; final approval of manuscript.

106. Chavez J♦, Czuczman MS, and Hernandez-Ilizaliturri FJ. Biology and management of diffuse large B-cell lymphoma. Contemporary Oncology 2(1):28-38, 2010.

Role:  Conception and design; collection and assembly of data; data analysis and interpretation; manuscript writing; final approval of manuscript.

107. Olejniczak SH^, Blickwedehl J, Belicha-Villanueva A♦, Bangia N, Hernandez-Ilizaliturri FJ, Clements JL, Czuczman MS.  Distinct molecular mechanisms responsible for bortezomib-induced death of therapy-resistant versus -sensitive B-NHL cells.  Blood (published ahead of print) Oct 2010; doi:10.1182/blood-2009-12-259754.  116: 5605-5614, 2010.  PMID: 20930068

Role:  Conception and design; conduction of experiments, provision of patients samples; collection and assembly of data; data analysis and interpretation; manuscript writing; final approval of manuscript

108. Wilson W, Hernandez-Ilizaliturri FJ, Dunleavy K, Little R, and O’Connor OA. Novel disease targets and management approaches for diffuse large B-cell lymphoma (DLBCL).  Leukemia and Lymphoma 51(supp 1): 1-10, 2010. PMID: 20658952

Role:  Conception and design; collection and assembly of data; data analysis and interpretation; manuscript writing; final approval of manuscript.

109. Ngamphaiboon N♦, Pukiat S♦, Kandimalla Y, Hernandez-Ilizaliturri FJ, and Rooney JJ. Diffuse Large B Cell Lymphoma Presenting as Pancoast Tumor. Journal of Clinical Oncology 28:e254-256, 2010. PMID: 20385989.

Role:  Conception and design; provision of study materials or patients; collection and assembly of data; data analysis and interpretation; manuscript writing; final approval of manuscript.

110. Sher T, Miller KC, Lawrence D, Whitworth A, Hernandez-Ilizaliturri F, Czuczman MS, Miller A, Lawrence W, Bilgrami SA, Sood R, Wood MT, Block AW, Lee K, Chanan-Khan AA. Efficacy of lenalidomide in patients with chronic lymphocytic leukemia with high-risk cytogenetics. Leuk Lymphoma, 2010; 51:85-88.  PMID: 20055660

Role:  Provision of study materials or patients; collection and assembly of data; data analysis and interpretation; manuscript writing; final approval of manuscript.

111. Riaz W♦, Hernandez-Ilizaliturri FJ, Czuczman MS. Strategies to enhance rituximab anti-tumor activity in the treatment of CD20-positive B-cell neoplasms. Immunol Res. 2010; 46:192-205. PMID: 19763890

Role:  Conception and design; collection and assembly of data; data analysis and interpretation; manuscript writing; final approval of manuscript.

112. Hernandez-Ilizaliturri FJ and Czuczman MS. Therapeutic Options in Relapsed or Refractory Diffuse Large B-cell Lymphoma Part 2. Current Treatment Approaches. Oncology. 2009; 23:610-5. PMID: 19626827

Role:  Conception and design; collection and assembly of data; data analysis and interpretation; manuscript writing; final approval of manuscript.

113. Hernandez-Ilizaliturri FJ and Czuczman MS. Therapeutic Options in Relapsed or Refractory Diffuse Large B-cell Lymphoma Part 1. Current Treatment Approaches. Oncology. 2009; 23:546-53. PMID: 19544696

Role:  Conception and design; collection and assembly of data; data analysis and interpretation; manuscript writing; final approval of manuscript.

114. Hernandez-Ilizaliturri FJ and Czuczman MS. A Review of Nelarabine in the treatment of T-cell lymphoblastic leukemia/lymphoma. Clinical Medicine: Therapeutics, 2009; 1:505-511.

Role:  Conception and design; collection and assembly of data; data analysis and interpretation; manuscript writing; final approval of manuscript.

115. Khubchandani S♦, Czuczman MS, and Hernandez-Ilizaliturri FJ. Dacetuzumab, a humanized monoclonal antibody against CD40 for the treatment of hematological malignancies. Current Opinion in Invest Drugs 2009; 10(6):579-587. PMID: 19513947

Role:  Conception and design; collection and assembly of data; data analysis and interpretation; manuscript writing; final approval of manuscript.

116. Gerber HP, Kung-Sutherland M, Stone I, Morris-Tilden C, Miyamoto J, McCormick R, Alley S, Okeley N, Hayes B, Hernandez-Ilizaliturri FJ, Benjamin D, and Grewal IS. Potent antitumor activity of the anti-CD19 auristatin antibody-drug conjugate hBU12-vcMMAE against rituximab sensitive and resistant lymphomas. Blood, Jan 2009; pre-published online doi:10.1182/blood-2008-09-17914. 2009; 113:4352-4361. PMID: 19147785

Role:  Provision of samples; data analysis and interpretation; manuscript writing; final approval of manuscript

117. Goldenberg DM, Rossi EA, Stein R, Cardillo TM, Czuczman MS, Hernandez-Ilizaliturri FJ, Hansen HS, and Chang C Properties and structure- function relationships of veltuzumab (hA20), a humanized anti-CD20 monoclonal antibody. Published ahead of Print. Blood, Oct 2008; doi:10.1182/blood-2008-07-168146. 2009; 113, 1062-1070. PMID: 18941114

Role:  Conception and design; conduction of experiments, provision of samples; collection and assembly of data; data analysis and interpretation; manuscript writing; final approval of manuscript

118. Hoppe RT, Advani RH, Ambinder RF, Bierman PJ, Bloomfield CD, Blum K, Dabaja B, Djulbegovic B, Forero A, Gordon LI, Hernandez-Ilizaliturri FJ, Hudson MM, Kaminski MS, Love G, Maloney DG, Mansur D, Mauch PM, Moore JO, Schilder RJ, Weiss LM, Winter JN, Yahalom J, Zelenetz AD. Hodgkin disease/lymphoma. J Natl Compr Canc Netw. 2008; 6:594-622. PMID: 18597713

Role:  Conception and design; collection and assembly of data; data analysis and interpretation; manuscript writing; final approval of manuscript.

119. Patel M♦, Ailawadhi S♦, Hernandez-Ilizaliturri F, Wilding GE. Vascular endothelial growth factor polymorphisms in early-stage non-small-cell lung cancer. J Clin Oncol. 2008; 26:3289-90. PMID: 18591568

Role:  Manuscript writing; final approval of manuscript.

120. Czuczman MS, Olejniczak S^, Gowda A♦, Kotowski A♦, Binder A♦, Kaur H♦, Knight J, Starostik P, Deans JP, and Hernandez-Ilizaliturri FJ. Acquirement of Rituximab Resistance in Lymphoma Cell Lines is Associated with Both a Global CD20 Gene and Protein Down-Regulation Regulated at the Pre- and Post-Transcriptional Level. Clin Cancer Res. 2008; 14:1561-70. PMID: 18316581

Role:  Conception and design; conduction of experiments, provision of patients samples; collection and assembly of data; data analysis and interpretation; manuscript writing; final approval of manuscript

121. Olejniczak S^, Hernandez-Ilizaliturri FJ, Clements JL, and Czuczman MS. Acquired Resistance to Rituximab Is Associated with Chemotherapy Resistance Resulting From Down-Regulation of Bax and Bak. Clinical Cancer Research 2008; 14:1550-60. PMID: 18316580

Role:  Conception and design; conduction of experiments, provision of patients samples; collection and assembly of data; data analysis and interpretation; manuscript writing; final approval of manuscript

122. Hernandez-Ilizaliturri FJ, Chisti MM♦, Makhoul I, MD, Claxton D, and Ballard JO. Combined B-Cell and T-Cell Disorders. E-Medicine 2008.

Role:  Conception and design; collection and assembly of data; data analysis and interpretation; manuscript writing; final approval of manuscript.

123. Benekli M, Smiley SL, Younis T, Czuczman MS, Hernandez-Ilizaliturri F, Bambach B, Battiwalla M, Padmanabhan S, McCarthy PL Jr, Hahn T. Intensive conditioning regimen of etoposide (VP-16), cyclophosphamide and carmustine (VCB) followed by autologous hematopoietic stem cell transplantation for relapsed and refractory Hodgkin's lymphoma. Bone Marrow Transplantation 2008; 41:613-9. PMID: 18071290

Role:  Provision of study materials or patients; collection and assembly of data; data analysis and interpretation; manuscript writing; final approval of manuscript.

124. Reddy N♦, Hernandez-Ilizaliturri FJ, Deeb G, Roth M♦, Vaughn M, Knight J, Wallace P, and Czuczman MS. Immunomodulatory drugs (IMiDs) lenalidomide and actimid stimulate NK-cell function, alter cytokine production by Dendritic Cells (DC’s), and inhibit angiogenesis enhancing the anti-tumor activity of rituximab in vivo. Br J Haematol. 2008; 140:36-45. PMID: 17995965

Role:  Conception and design; conduction of experiments, provision of patients samples; collection and assembly of data; data analysis and interpretation; manuscript writing; final approval of manuscript

125. Vinjamaram S♦ and Hernandez-Ilizaliturri FJ. The use of Galiximab in non-Hodgkin’s Lymphoma (NHL). Clin Lymphoma Myeloma. 2008; 8:277-82. PMID: 18854281

Role:  Conception and design; collection and assembly of data; data analysis and interpretation; manuscript writing; final approval of manuscript.

126. Cruz R♦, Hernandez-Ilizaliturri FJ, Olejniczak S^, Deeb G, Knight J, Wallace P, and Czuczman MS. CD52 over-expression affects rituximab-associated complement-mediated cytotoxicity (CMC) but not antibody-dependent cellular cytotoxicity (ADCC): Pre-clinical evidence targeting CD52 with alemtuzumab to reverse acquired resistance to rituximab in Non-Hodgkin’s Lymphoma (NHL) Leukemia and Lymphoma 2007; 48:2424-36. PMID: 18067019

Role:  Conception and design; conduction of experiments, provision of patients samples; collection and assembly of data; data analysis and interpretation; manuscript writing; final approval of manuscript

127. Maddipatla S♦, Hernandez-Ilizaliturri FJ, Knight J, Czuczman MS. Augmented Anti-Tumor Activity against B-cell Lymphoma by a Combination of Monoclonal Antibodies (mAbs) Targeting TRAIL-R1 and CD20. Clin Cancer Res. 2007; 13:4556-64. PMID: 17671142

Role:  Conception and design; conduction of experiments, provision of patients samples; collection and assembly of data; data analysis and interpretation; manuscript writing; final approval of manuscript

128. Vinjamaram S♦, Hernandez-Ilizaliturri FJ, Estrada D, Rajdev L, and Sparano JA. Non-Hodgkin’s Lymphoma. E-medicine Journal. 2007

Role:  Conception and design; collection and assembly of data; data analysis and interpretation; manuscript writing; final approval of manuscript.

129. Hernandez-Ilizaliturri FJ. Combined B- and T-cell immunodeficiency disorders. E-medicine Journal 2007

Role:  Conception and design; collection and assembly of data; data analysis and interpretation; manuscript writing; final approval of manuscript.

130. Chanan-Khan A, Miller KC, Musial L, Lawrence D, Padmanabhan S, Takeshita K, Porter CW, Goodrich DW, Bernstein ZP, Wallace P, Spaner D, Mohr A, Byrne C, Hernandez-Ilizaliturri F, Chrystal C, Starostik P, Czuczman MS. Clinical Efficacy of Lenalidomide in Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia: Results of a Phase II Study. J Clin Oncol. 2006;  24:5343-5349. PMID: 17088571

Role:  Provision of study materials or patients; collection and assembly of data; data analysis and interpretation; manuscript writing; final approval of manuscript.

131. Hoppe RT, Advani RH, Bierman PJ, Bloomfield CD, Buadi F, Djulgegovic B, Forero A, Gordon LI, Hernandez-Ilizaliturri FJ, Kaminski MS, Love G, Maloney DG, Mauch PM, Moore JO, Schilder RJ, Weiss L, Winter JN, Yahalom J, Zelenetz AD; National Comprehensive Cancer Network. Hodgkin disease/lymphoma. Clinical practice guidelines in oncology. J National Comprehensive Cancer Network. 2006; 4:210-30. PMID: 16507269

Role:  Conception and design; collection and assembly of data; data analysis and interpretation; manuscript writing; final approval of manuscript.

132. Chadha K♦, Hernandez-Ilizaliturri F, and Javle M. Primary Esophageal Lymphoma: Case Series and review of the literature. Dig Dis Sci. 2006; 51:77-83. PMID: 16416216

Role:  Conception and design; provision of study materials or patients; collection and assembly of data; data analysis and interpretation; manuscript writing; final approval of manuscript.

133. Hernandez-Ilizaliturri FJ, Jupudy V♦, Reising S♦, Repasky E.A. and Czuczman M.S. Concurrent Administration of Granulocyte Colony-Stimulating Factor (G-CSF) Or Granulocyte-Monocyte Colony-Stimulating Factor (GM-CSF) Enhances Rituximab’s Biological Activity and up regulates CD11b in a Severe Combined Immunodeficiency (SCID) Mouse Lymphoma Model. Leukemia and Lymphoma. 2005; 46:1775-84. PMID: 16263581

Role:  Conception and design; conduction of experiments, provision of patients samples; collection and assembly of data; data analysis and interpretation; manuscript writing; final approval of manuscript

134. Hernandez-Ilizaliturri FJ, Reddy N♦, Holkova B♦, Ottman E♦, and Czuczman MS. Immunomodulatory Drug CC5013 or CC4047 and Rituximab Enhance Anti-Tumor Activity in A Severe Combined Immunodeficiency (SCID) Mouse Lymphoma Model. Clin Cancer Res. 2005; 11:5984-92. PMID: 16115943

Role:  Conception and design; conduction of experiments, provision of patients samples; collection and assembly of data; data analysis and interpretation; manuscript writing; final approval of manuscript

135. Ramanarayanan R♦, Hernandez-Ilizaliturri1FJ, Chanan-Khan A, and Czuczman MS. Pro-apoptotic therapy with the oligonucleotide Genasense™ (oblimersen sodium) targeting Bcl-2 protein expression enhances the biological anti-tumor activity of rituximab. The British Journal of Hematology, 2004; 127:519-30. PMID: 15566355

Role:  Conception and design; conduction of experiments, provision of patients samples; collection and assembly of data; data analysis and interpretation; manuscript writing; final approval of manuscript

136. Hernandez-Ilizaliturri FJ, Gowda A♦, and Czuczman MS. Development of Targeted Therapies for B-cell Non-Hodgkin’s Lymphoma and Multiple Myeloma. Clin Adv Hem Onc. 2004 2:606-618.  PMID: 16163245

Role:  Conception and design; collection and assembly of data; data analysis and interpretation; manuscript writing; final approval of manuscript.

137. Czuczman MS, Koryzna A, Mohr A, Stewart C, Donohue K, Blumenson L, Bernstein ZP, McCarthy P, Alam A, Hernandez-Ilizaliturri FJ, Skipper M, Brown K, Chanan-Khan A, Klippenstein D, Loud P, Rock MK, Benyunes M, Grillo-Lopez A,  Bernstein SH.  Rituximab in Combination with Fludarabine Chemotherapy in Low-Grade or Follicular Lymphoma. Journal of Clinical Oncology 2005; 23:694-704. PMID: 15681517

Role:  Provision of study materials or patients; collection and assembly of data; data analysis and interpretation; manuscript writing; final approval of manuscript.

138. Hernandez-Ilizaliturri FJ, Bir A♦, and Czuczman MS. The potential use of Alemtuzumab in rituximab-resistant Lymphoproliferative disorders. CLL Cutting Edge 2004, 7:8-10.

Role:  Conception and design; collection and assembly of data; data analysis and interpretation; manuscript writing; final approval of manuscript.

139. Hernandez-Ilizaliturri FJ, Tan D, Cipolla D♦, Connolly G♦, Deeb G, and Ramnath N. Multimodality therapy for Thymic Carcinoma (TCA): Results of a 30 Year single-institution experience. American Journal of Clinical Oncology 2004; 27:68-72.  PMID: 14758136

Role:  Conception and design; collection and assembly of data; data analysis and interpretation; manuscript writing; final approval of manuscript.

140. Ramanarayanan J♦, Krishann G, Hernandez-Ilizaliturri FJ. Factor VII. 2004; E-medicine Journal.

Role:  Conception and design; collection and assembly of data; data analysis and interpretation; manuscript writing; final approval of manuscript.

141. Hernandez-Ilizaliturri FJ, Jupudy V♦, Oflazoglu E, Huberman A, Ostberg J, Repasky EA, and Czuczman MS. Neutrophils contribute to the biological anti-tumor activity of Rituximab in a non-Hodgkin’s lymphoma severe combined immunodeficiency (SCID) mouse model. Clinical Cancer Research 2003: 9; 5866-5873. PMID: 14676108

Role:  Conception and design; conduction of experiments, provision of patients samples; collection and assembly of data; data analysis and interpretation; manuscript writing; final approval of manuscript

142. Hernandez-Ilizaliturri FJ, Gada P♦, and Czuczman MS. Emerging humanized monoclonal antibodies against Non-Hodgkin’s Lymphoma. Cancer Conference Highlights: 2002 ASH Meeting.  2003; 7:8-10

Role:  Conception and design; collection and assembly of data; data analysis and interpretation; manuscript writing; final approval of manuscript.

143. Ramnath N, Hernandez FJ, and Bepler G. Neoadjuvant Chemotherapy for Non-Small Cell Lung Cancer - Will the Answer Lie in Targeted Chemotherapy? Oncology Spectrums 2002; 3: 27-34. PMID: 11709570

Role:  Conception and design; collection and assembly of data; data analysis and interpretation; manuscript writing; final approval of manuscript.

144. Ramnath N, Hernandez FJ, Tan D, Huberman JA, Natarajan N, Beck AF, Hyland A, Todorov I, Brooks JSJ, and Bepler G. MCM2 is an Independent Predictor Factor of Survival in Patients with Non-Small Cell Lung Cancer. Journal of Clinical Oncology 2001; 19:4259-4266.

Role:  Conception and design; collection and assembly of data; data analysis and interpretation; manuscript writing; final approval of manuscript.

145. Hernandez-Ilizaliturri FJ and Sendowski M. Recent Advances in the Molecular Biology of Non-Hodgkin’s Lymphoma. Fellow Reporter 4: May 2001

Role:  Conception and design; collection and assembly of data; data analysis and interpretation; manuscript writing; final approval of manuscript.

146. Hernandez-Ilizaliturri FJ. The Emerging Role of Molecular Biology in the pathophysiology of Non-Hodgkin’s Lymphoma. Fellow Reporter 3: April 2001.

Role:  Conception and design; collection and assembly of data; data analysis and interpretation; manuscript writing; final approval of manuscript.